AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 4.72 |
Market Cap | 25.26M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.75 |
PE Ratio (ttm) | -6.3 |
Forward PE | n/a |
Analyst | Buy |
Ask | 4.89 |
Volume | 25,415 |
Avg. Volume (20D) | 30,131 |
Open | 4.85 |
Previous Close | 4.60 |
Day's Range | 4.72 - 4.89 |
52-Week Range | 3.20 - 11.79 |
Beta | undefined |
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioident...
Analyst Forecast
According to 1 analyst ratings, the average rating for LPCN stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 111.73% from the latest price.
Next Earnings Release
Analysts project revenue of $200.00K, reflecting a -7.49% YoY shrinking and earnings per share of -0.38, making a -9.52% decrease YoY.